Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nat Med. 2011 Jul 24;17(8):941-3. doi: 10.1038/nm.2407.

    Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.

    Source

    Committee on Cancer Biology, University of Chicago, Chicago, Illinois, USA.

    Abstract

    Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-induced second malignant neoplasms (SMNs). We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults. The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure. These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.

    Comment in

    PMID:
    21785431
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3229923
    Free PMC Article

    Images from this publication.See all images (1)Free text

    Figure 1

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk